Document is current
Any future updates will be listed below
-
Authors
Costa, Olivia S.
Connolly, Stuart J.
Sharma, Mukul
Beyer-Westendorf, Jan
Christoph, Mary J.
Lovelace, Belinda
Coleman, Craig I.
- License Information
-
More Information
Article History
Received: 23 March 2022
Accepted: 2 June 2022
First Online: 16 June 2022
Declarations
:
: The ANNEXA-4 study was approved by site institutional review boards (IRBs). Informed consent was obtained from participants or legal representatives. This study was approved by the IRB at Hartford Hospital. Due to the retrospective nature and de-identification of the synthetic control arm, informed consent was waived.
: Not applicable.
: Dr. Costa has received presentation fees from Janssen Pharmaceuticals. Dr. Connolly has received grant support and consulting fees from Alexion, AstraZeneca Rare Disease, Bristol Myers Squibb, Bayer, Boehringer Ingelheim, Javelin, and Daiichi Sankyo. Dr. Sharma has received grants from Bayer AG, Bristol Myers Squibb, and Alexion, AstraZeneca Rare Disease and personal fees from Pfizer, Janssen Pharmaceuticals, and Bayer AG. Dr. Beyer-Westendorf has received grant support, lecture fees, and advisory board fees from Bayer AG and Daiichi Sankyo and grant support from Pfizer. Drs. Christoph and Lovelace are employees of Alexion, AstraZeneca Rare Disease. Dr. Coleman has received research funding and/or consulting honoraria from Janssen Scientific Affairs, LLC, Bayer AG, and Alexion, AstraZeneca Rare Disease.
